Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke

Neurology

Volumn 50, Issue 4, 1998, Pages 883-890

  Fagan, S C ^a,b   Morgenstern, L B ^c   Petitta, A ^b   Ward, R E ^b   Tilley, B C ^b   Marler, J R ^d   Levine, S R ^b   Broderick, J P ^g   Kwiatkowski, T G ^e   Frankel, M ^f   Brott, T G ^g   Walker, M D ^d  

^a WAYNE STATE UNIVERSITY   (United States)

^b Henry Ford Health System   (United States)

^c UNIVERSITY OF TEXAS   (United States)

^d NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^e LONG ISLAND JEWISH MEDICAL CENTER   (United States)

^f EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; PLACEBO;

ACUTE DISEASE; AGED; ARTICLE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEATH; DRUG COST; HEALTH CARE COST; HOSPITAL COST; HUMAN; NURSING HOME; PRIORITY JOURNAL; REHABILITATION;

EID: 0031946671     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/WNL.50.4.883     Document Type: Article

References (26)

1. Dobkin B. The economic impact of stroke. Neurology 1995; 45(suppl 1):S6-S9.
2. Taylor TN, Davis PH, Torner JC, Holmes J, Meyer JW, Jacobson MF. Lifetime cost of stroke in the United States. Stroke 1996;27:1459-1466.
3. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995;333:1581-1587.
4. Eddy DM. Practice policies - guidelines for methods. JAMA 1990;263:1839-1841.
5. Rubenstein RY. Simulation of Monte Carlo Method. New York: Wiley, 1981:5-6.
6. van Sweiten JC, Koudstaal PJ, Visser MC, Schouten HJA, van Gijn J. Interobserver agreement for the assessment of handicap in stroke patients. Stroke 1988;19:604-607.
7. Oster G, Huse DM, Lacey MJ, Epstein AM. Cost-effectiveness of ticlopidine in preventing stroke in high-risk patients. Stroke 1994;25:1149-1156.
8. Whisnant JP. Natural history of transient ischemic attack and ischemic stroke. In: Whisnant JP, ed. Stroke: populations, cohorts and clinical trials. Boston, MA: Butterworth-Heinemann, 1993.
9. Sacco RL, Shi T, Zamanillo MC, Kargman DE. Predictors of mortality and recurrence after hospital cerebral infarction in an urban community: the Northern Manhattan Stroke Study. Neurology 1994;44:626-634.
10. Solomon NA, Glick HA, Russo CJ, Lee J, Schulman KA. Patient preferences for stroke outcomes. Stroke 1994;25:1721-1725.
11. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med 1995;332:1418-1424.
12. Holloway RG, Witter DM, Lawton KB, Lipscomb J, Samsa G. Inpatient costs of specific cerebrovascular events at five academic medical centers. Neurology 1996;46:854-860.
13. Burr D. 1996 Physician compensation report. Modern Healthcare 1996;July 15:33-36.
14. Falconer JA, Naughton BJ, Strasser DC, Sinacore JM. Stroke inpatient rehabilitation: a comparison across age groups. J Am Geriatr Soc 1994;42:39-44.
15. Granger CV, Hamilton BB, Fiedler RC. Discharge outcome after stroke rehabilitation. Stroke 1992;23:978-982.
16. Alexander MP. Stroke rehabilitation outcome: a potential use of predictive variables to establish levels of care. Stroke 1994; 25:128-134.
17. Lee JA, Huber J, Stason WB. Poststroke rehabilitation in older Americans. The Medicare experience. Med Care 1996;34: 811-825.
18. Weiner JM, Illston LH, Hanley RJ. Sharing the burden: strategies for public and private long-term care insurance. Washington, DC: Brookings Institute, 1993.
19. Armitage P, Berry G. Statistical methods in medical research. 2nd ed. Boston, MA: Blackwell Scientific, 1985:82-83.
20. The National Institute of Neurological Disorders and Stroke (NINDS) rt-PA Stroke Study Group. A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care. Stroke 1997;28:1530-1540.
21. Lyden PD, Rapp K, Babcock T, Rothrock J. Ultra-rapid identification, triage and enrollment of stroke patients into clinical trials. J Stroke Cerebrovasc Dis 1994;4:106-113.
22. Tilley BC, Lyden PD, Brott TG, et al. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke. Arch Neurol 1997;54:1466-1474.
23. Sacco SE, Whisnant JP, Broderick JP, Phillips SJ, O'Fallon M. Epidemiological characteristics of lacunar infarcts in a population. Stroke 1991;1236-1241.
24. Sacco RL, Wolf PA, Kannel WB, McNamara PM. Survival and recurrence following stroke. The Framingham Study. Stroke 1982;13:290-295.
25. Nussbaum ES, Heros RC, Erickson DL. Cost-effectiveness of carotid endarterectomy. Neurosurgery 1996;38:237-244.
26. Foran RM, Brett JL, Wuff PH. Evaluating the cost impact of intravenous antibiotic dosing frequencies. DICP, Ann Pharmacother 1991;25:546-552.